PAS
ALNY icon

Point72 Asia (Singapore)’s Alnylam Pharmaceuticals ALNY Stock Holding History

Point72 Asia (Singapore)’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		$673K Buy
1,474
+656
+80% +$267K 0.1% 137
2025
Q2 		$267K Sell
818
-14,188
-95% -$3.93M 0.05% 296
2025
Q1 		$4.05M Buy
+15,006
New +$3.86M 1.06% 21

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Point72 Asia (Singapore)'s ALNY Position: Q3 2025 in Review

Point72 Asia (Singapore) increased its Alnylam Pharmaceuticals (ALNY) stake by 80% in Q3 2025, buying an estimated $267K and bringing the position to 1,474 shares worth $673K. The position accounts for 0.1% of the portfolio, ranked #137.

Point72 Asia (Singapore) first reported a position in ALNY in Q1 2025 and has held it in 3 quarters since. The position peaked at $4.05M in Q1 2025. 821 funds tracked by Wall St. Rank hold ALNY as of Q3 2025.

  • Point72 Asia (Singapore) held 1,474 shares of Alnylam Pharmaceuticals worth $673K as of Q3 2025.
  • Point72 Asia (Singapore) bought 656 Alnylam Pharmaceuticals shares in Q3 2025, an estimated $267K.
  • Alnylam Pharmaceuticals made up 0.1% of Point72 Asia (Singapore)'s portfolio in Q3 2025, its #137 holding.
  • Point72 Asia (Singapore) first reported a position in Alnylam Pharmaceuticals in Q1 2025 and has held it in 3 quarters since.
  • Point72 Asia (Singapore)'s Alnylam Pharmaceuticals position peaked at $4.05M in Q1 2025.
  • 821 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q3 2025.

Based on Point72 Asia (Singapore)'s 13F filing for Q3 2025, filed 14 Nov 2025.